{"id":"W4404353984","doi":"10.1016/s0140-6736(24)01774-4","title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","year":2024,"lang":"en","type":"article","venue":"The Lancet","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Oxaliplatin; Rituximab; Medicine; Refractory (planetary science); Gemcitabine; Open label; Diffuse large B-cell lymphoma; Internal medicine; Oncology; Lymphoma; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Colorectal cancer; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001589018,0.001938147,0.002754168,0.0003672561,0.0002559627,0.001265413,0.00100386,0.001766981,0.005286472],"category_scores_gemma":[0.001123477,0.0006117486,0.002783914,0.0004382346,0.001512189,0.001500861,0.0006359299,0.003520366,0.001258129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001024291,"about_ca_system_score_gemma":0.0009161003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00112539,"about_ca_topic_score_gemma":0.002745536,"domain_scores_codex":[0.999507,0.0002597111,0.00001963593,0.00008309776,0.0000263973,0.0001041749],"domain_scores_gemma":[0.9993814,0.0001738574,0.0001284717,0.00004827349,0.00002699543,0.0002409199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.97417,0.001806207,0.0005285674,0.0007929947,0.001311202,0.00003755852,0.00005488821,0.0004828121,0.001846278,0.0001618075,0.001288222,0.01751952],"study_design_scores_gemma":[0.9619884,0.03457868,0.001335051,0.00004925374,0.0005564176,0.0000438336,0.00003364744,0.0002567818,0.0001990497,0.0002359065,0.0007075939,0.00001539729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773746,0.01433875,0.0006182967,0.00161602,0.0008242913,0.001329094,0.00120225,0.0001946364,0.002502104],"genre_scores_gemma":[0.9816613,0.00643211,0.001399885,0.002390673,0.0003822767,0.001677223,0.001799621,0.00005267368,0.004204204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005286472,"threshold_uncertainty_score":0.01768506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07879406084213593,"score_gpt":0.3781979043351438,"score_spread":0.2994038434930079,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}